Emergent BioSolutions vs Organogenesis
EBS and ORGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EBS and ORGO compare
Emergent BioSolutions is the larger company, worth 2.8 times as much as Organogenesis ($297M against $104M).
Emergent BioSolutions grew revenue faster over the last twelve months (−17.7% versus −24.3% for Organogenesis).
Organogenesis keeps more of each dollar of sales as profit, with a net margin of −38.4% compared with −40.2% at Emergent BioSolutions.
Organogenesis scores higher on the StockData Score (8 against 6 for Emergent BioSolutions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EBS | ORGO |
|---|---|---|
| Size and price | ||
| Market cap | $297M | $104M |
| Share price | $5.79 | $0.810 |
| Change, 1 year | −46.4% | −87.5% |
| Change, 5 years | −85.6% | −91.8% |
| Beta (5Y) | 1.84 | 1.14 |
| Employees | 900 | 854 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 2 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× | 0.3× (better) |
| P/B | 0.9× | 0.9× (better) |
| P/FCF | 1.6× | – |
| FCF yield | 63.5% (better) | −0.06% |
| Fair value | $20.75 | – |
| Margin of safety | 72.1% | – |
| Growth | ||
| Revenue growth (TTM) | −17.7% (better) | −24.3% |
| Revenue growth, 5Y average | −14.0% | 10.8% (better) |
| Net income growth (TTM) | −443% (better) | −13568% |
| EPS growth (TTM) | −486% | – |
| EPS growth, 5Y average | −30.4% | 0.00% (better) |
| Profitability | ||
| Gross margin | 48.4% | – |
| Operating margin | −27.7% | −24.5% (better) |
| Net margin | −40.2% | −38.4% (better) |
| FCF margin | 29.0% (better) | −0.02% |
| Return on equity | −58.2% (better) | −72.2% |
| Return on invested capital | −17.3% (better) | −47.0% |
| Financial health | ||
| Debt / equity | 1.62 (better) | 0.00 |
| Interest coverage | −4.0× | – |
| Current ratio | 4.58 (better) | 3.32 |
| Altman Z-score | 0.33 | 0.44 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 9.2% | – |
| Shareholder yield | 9.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 87.1% | 53.2% |
| Held by insiders | 6.0% | – |
| Insider net buying, 12 months | −$986K (better) | −$988K |
| Short interest, % of float | 20.9% | – |
Go deeper
- EBS stock overview
- EBS income statement
- EBS valuation and score
- ORGO stock overview
- ORGO income statement
- ORGO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.